Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,861 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort.
Hayashi N, Fukai J, Nakatogawa H, Kawaji H, Yoshioka E, Kodama Y, Nakajo K, Uda T, Naito K, Kijima N, Okita Y, Kagawa N, Takahashi Y, Hashimoto N, Arita H, Takano K, Sakamoto D, Iida T, Arakawa Y, Kawauchi T, Sonoda Y, Mitobe Y, Ishibashi K, Matsuda M, Achiha T, Tomita T, Nonaka M, Hara K, Takebe N, Tsuzuki T, Nakajima Y, Ohue S, Nakajima N, Watanabe A, Inoue A, Umegaki M, Kanematsu D, Katsuma A, Sumida M, Shofuda T, Mano M, Kinoshita M, Mori K, Nakao N, Kanemura Y. Hayashi N, et al. Among authors: kodama y. Acta Neuropathol Commun. 2024 Oct 1;12(1):155. doi: 10.1186/s40478-024-01863-3. Acta Neuropathol Commun. 2024. PMID: 39354603 Free PMC article. No abstract available.
Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort.
Hayashi N, Fukai J, Nakatogawa H, Kawaji H, Yoshioka E, Kodama Y, Nakajo K, Uda T, Naito K, Kijima N, Okita Y, Kagawa N, Takahashi Y, Hashimoto N, Arita H, Takano K, Sakamoto D, Iida T, Arakawa Y, Kawauchi T, Sonoda Y, Mitobe Y, Ishibashi K, Matsuda M, Achiha T, Tomita T, Nonaka M, Hara K, Takebe N, Tsuzuki T, Nakajima Y, Ohue S, Nakajima N, Watanabe A, Inoue A, Umegaki M, Kanematsu D, Katsuma A, Sumida M, Shofuda T, Mano M, Kinoshita M, Mori K, Nakao N, Kanemura Y. Hayashi N, et al. Among authors: kodama y. Acta Neuropathol Commun. 2024 Jul 27;12(1):120. doi: 10.1186/s40478-024-01808-w. Acta Neuropathol Commun. 2024. PMID: 39061104 Free PMC article.
Prediction of MGMT promotor methylation status in glioblastoma by contrast-enhanced T1-weighted intensity image.
Sanada T, Kinoshita M, Sasaki T, Yamamoto S, Fujikawa S, Fukuyama S, Hayashi N, Fukai J, Okita Y, Nonaka M, Uda T, Arita H, Mori K, Ishibashi K, Takano K, Nishida N, Shofuda T, Yoshioka E, Kanematsu D, Tanino M, Kodama Y, Mano M, Kanemura Y. Sanada T, et al. Among authors: kodama y. Neurooncol Adv. 2024 Feb 1;6(1):vdae016. doi: 10.1093/noajnl/vdae016. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38410136 Free PMC article.
Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Ishihara N, Komatsu S, Yano Y, Fujishima Y, Ishida J, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Matsuura T, Tada T, Kodama Y, Fukumoto T. Ishihara N, et al. Among authors: kodama y. Anticancer Res. 2025 Jan;45(1):251-260. doi: 10.21873/anticanres.17412. Anticancer Res. 2025. PMID: 39740814
Comparison of different puncture needles used for endoscopic ultrasound-guided fine-needle biopsy of Gastrointestinal subepithelial lesions (≤ 2 cm) with respect to the adequacy of specimen collection: study protocol for a multicenter randomized prospective trial.
Yamashita Y, Ashida R, Shimokawa T, Ikeda T, Inatomi O, Ogura T, Kodama Y, Takeshita K, Takenaka M, Tsujimoto A, Nakai Y, Fujinaga Y, Kitano M. Yamashita Y, et al. Among authors: kodama y. Trials. 2024 Dec 28;25(1):852. doi: 10.1186/s13063-024-08654-0. Trials. 2024. PMID: 39732704 Free PMC article.
Publisher Correction: Anti-integrin αvβ6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.
Okabe M, Yamamoto S, Shiokawa M, Hisamatsu T, Yamazaki H, Nakanishi R, Hamada K, Kitamoto H, Kuwada T, Uza N, Sakatani A, Fujii T, Ohno M, Matsuura M, Shibuya T, Ohmiya N, Ooi M, Hoshi N, Moriya K, Tsuchiya K, Yamaguchi Y, Kunisaki R, Takahara M, Takagi T, Takehara T, Hirai F, Kakimoto K, Esaki M, Nakase H, Kinjo F, Torisu T, Kanmura S, Narimatsu K, Matsuoka K, Hiraga H, Yokoyama K, Honzawa Y, Naganuma M, Saruta M, Kodama Y, Chiba T, Seno H. Okabe M, et al. Among authors: kodama y. J Gastroenterol. 2024 Dec 27. doi: 10.1007/s00535-024-02203-x. Online ahead of print. J Gastroenterol. 2024. PMID: 39729094 No abstract available.
Improved visibility of palisade vessels within Barrett's esophagus using red dichromatic imaging: a retrospective cross-sectional study in Japan.
Ueda C, Tanaka S, Yoshizaki T, Abe H, Kinoshita M, Sakaguchi H, Takayama H, Hori H, Ishida R, Houki S, Tanabe H, Nishikawa E, Takao M, Takao T, Morita Y, Toyonaga T, Kodama Y. Ueda C, et al. Among authors: kodama y. Clin Endosc. 2024 Nov 11. doi: 10.5946/ce.2024.122. Online ahead of print. Clin Endosc. 2024. PMID: 39722141 Free article.
Authors' Reply to Noguchi et al. Comment on: "Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors Used in Patients with Diabetes and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database".
Sakamoto T, Miyamoto H, Hashizume J, Akamatsu H, Akagi T, Kodama Y, Hamano H, Zamami Y, Ohyama K. Sakamoto T, et al. Among authors: kodama y. Clin Drug Investig. 2024 Dec 24. doi: 10.1007/s40261-024-01414-7. Online ahead of print. Clin Drug Investig. 2024. PMID: 39718696 No abstract available.
1,861 results